Shareholders' Deficit (Tables)

3 Months Ended

Mar. 31, 2022

Stockholders' Equity Note [Abstract]

Schedule of changes in shareholders' equity (deficit)

Changes in shareholders’ deficit for the three months ended March 31, 2022 were as follows:

	Common Shares
	Shares	Amount		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income		Biohaven Shareholders' Equity (Deficit)		Non-controlling Interests		Total Shareholders' Equity (Deficit)
Balances as of December 31, 2021	66,933,531	$	1,676,792	$	169,656	$	(2,585,755)	$	(73)	$	(739,380)	$	(3,629)	$	(743,009)
Repurchase of preferred shares in consolidated subsidiary	1,232,629	152,673		(92,673)						60,000				60,000
Issuance of common shares as payment for agreements	2,037,921	253,779								253,779				253,779
Issuance of common shares under equity incentive plan	336,721	29,442		(30,193)						(751)				(751)
Non-cash share-based compensation expense				82,790						82,790				82,790
Net loss						(116,399)				(116,399)		(498)		(116,897)
Other comprehensive loss								(2,325)		(2,325)				(2,325)
Balances as of March 31, 2022	70,540,802	$	2,112,686	$	129,580	$	(2,702,154)	$	(2,398)	$	(462,286)	$	(4,127)	$	(466,413)

Changes in shareholders’ equity (deficit) for the three months ended March 31, 2021 were as follows:

	Common Shares
	Shares	Amount		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income		Biohaven Shareholders' Equity (Deficit)		Non-controlling Interests		Total Shareholders' Equity (Deficit)
Balance as of December 31, 2020	60,436,876	$	1,249,547	$	98,938	$	(1,739,169)	$	314	$	(390,370)	$	(1,819)	$	(392,189)
Issuance of common shares, net of offering costs	4,037,204	308,243		—		—		—		308,243		—		308,243
Issuance of common shares as part of acquisition	115,836	10,673		—		—		—		10,673		—		10,673
Issuance of common shares as payment for license agreements	110,998	10,243		—		—		—		10,243		—		10,243
Issuance of common shares under equity incentive plan	365,554	25,315		(23,933)		—		—		1,382		—		1,382
Non-cash share-based compensation expense	—	—		48,726		—		—		48,726		—		48,726
Net loss	—	—		—		(264,968)		—		(264,968)		(360)		(265,328)
Other comprehensive income	—	—		—		—		95		95		—		95
Balance as of March 31, 2021	65,066,468	$	1,604,021	$	123,731	$	(2,004,137)	$	409	$	(275,976)	$	(2,179)	$	(278,155)